canine dermatitis
- December 23, 2025
Zenrelia (generic name: ilunocitinib) is a prescription medication developed by Elanco Animal Health for use in dogs aged 12 months or older, intended to control itching (pruritus) associated with allergic dermatitis and to manage atopic dermatitis.
In simpler terms: it's a once‐daily oral tablet for dogs with skin allergy problems, designed to help stop the cycle of itching and scratching that leads to skin damage, inflammation and discomfort.
Why was Zenrelia developed?
Many dogs suffer from allergic skin disease – for example, environmental allergies, flea‐bite hypersensitivity, food allergy, or atopic dermatitis. As Elanco puts it, about 17 million dogs in the U.S. alone suffer from some form of allergic skin disease.
In dogs, chronic itching leads to scratching, licking, skin lesions, secondary infections, ear problems, paw irritation, and a reduced quality of life for both the pet and the owner. The idea behind Zenrelia is to offer another treatment option — especially for dogs
- December 23, 2025
Dogs with allergic dermatitis (food, flea, environmental) often endure intense itching, redness, chewing/licking of skin, and recurrent infections. Two oral medications that target this problem are Zenrelia and Apoquel. They share similarities but also have important differences in their mechanisms, dosing, safety concerns and practical use.
What each drug is / approved for
Apoquel
- The active ingredient is Oclacitinib.
- Apoquel is approved for dogs at least 12 months old for the control of pruritus (itching) associated with allergic dermatitis and the control of atopic dermatitis.
- It’s been on the market for a while (since ~2013 in the U.S.).
- Mechanism: it’s a Janus kinase (JAK) inhibitor (primarily JAK1) that disrupts itch- and inflammation-related signalling.
Zenrelia
- The active ingredient is Oclacitinib.
